Chyu Kuang-Yuh, Nilsson Jan, Shah Prediman K
Division of Cardiology, Cedars Sinai Medical Center, Suite 5531, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
Curr Atheroscler Rep. 2007 Aug;9(2):104-9. doi: 10.1007/s11883-007-0005-8.
This review summarizes experimental findings that highlight the complex roles of the immune system in atherogenesis. Immune activation can have either proatherogenic or atheroprotective effects. Immune-modulation therapy via an active or passive immunization strategy aims to exploit the atheroprotective aspects of the immune system to modulate atherosclerosis. Several experimental studies have demonstrated that such an approach is feasible and effective, raising the tantalizing possibility that an atheroprotective vaccine can be developed for clinical testing. Several potential immunogens have been identified and tested for their atheroprotective efficacy with variable results. Although several questions such as choice of optimal antigens, choice of most effective adjuvants, the optimal route of administration, durability of effects, and safety remain to be answered, we believe that a vaccine-based approach to manage atherosclerotic cardiovascular disease is a potentially viable paradigm.
本综述总结了突出免疫系统在动脉粥样硬化发生中复杂作用的实验结果。免疫激活可产生促动脉粥样硬化或抗动脉粥样硬化的作用。通过主动或被动免疫策略进行的免疫调节治疗旨在利用免疫系统的抗动脉粥样硬化特性来调节动脉粥样硬化。多项实验研究表明，这种方法是可行且有效的，这增加了开发用于临床试验的抗动脉粥样硬化疫苗的诱人可能性。已鉴定出几种潜在的免疫原并测试了它们的抗动脉粥样硬化功效，结果各不相同。尽管诸如最佳抗原的选择、最有效佐剂的选择、最佳给药途径、效果的持久性和安全性等几个问题仍有待解答，但我们认为基于疫苗的方法来管理动脉粥样硬化性心血管疾病是一种潜在可行的范例。
